Details for Patent: 8,313,754

Title:	Ophthalmic compositions containing a synergistic combination of two polymers
Abstract:	Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.
Inventor(s):	Chowhan; Masood A. (Arlington, TX), Chen; Huagang (Arlington, TX)
Assignee:	Novartis AG (Basel, CH)
Filing Date:	Apr 11, 2011
Application Number:	13/083,823
Claims:	1. An aqueous composition suitable for topical ophthalmic administration comprising: an ophthalmically acceptable drug; a viscosity enhancing amount of a combination of two polymers having a synergistic effect on the composition's viscosity, the combination of two polymers being hydroxypropyl methylcellulose (HPMC) and hydroxyethylcellulose (HEC), wherein the concentration of HPMC is in a range from 0.05 to 0.5% and HEC is in a range from 0.05 to 0.5%; wherein the aqueous composition has a viscosity that is greater than 150% of a sum of viscosities of two solutions, each of the two solutions respectively including only one of the two polymers. 2. The composition of claim 1 wherein the total concentration of the two polymers ranges from 0.05-3.0% (w/w). 3. The composition of claim 1 wherein the total concentration of the two polymers ranges from 0.2-2.0% (w/w). 4. The composition of claim 3 wherein the concentration of HEC in the composition is in a range from 0.1 to 0.2%. 5. The composition of claim 3 wherein the concentration of HPMC in the composition is in a range from 0.05 to 0.5%. 6. The composition of claim 1 further comprising an ingredient selected from the group consisting of pharmaceutically acceptable buffering agents; preservatives; non-ionic tonicity-adjusting agents; surfactants; solubilizing agents; stabilizing agents; comfort-enhancing agents; emollients; pH-adjusting agents; and lubricants. 7. The composition of claim 1 wherein the ophthalmic drug is selected from the group consisting of anti-glaucoma agents; anti-angiogenesis agents; anti-infective agents; non-steroidal and steroidal anti-inflammatory agents; growth factors; immunosuppressant agents; and anti-allergic agents. 8. The composition of claim 1 wherein the concentration of HEC in the composition is in a range from 0.1 to 0.2%. 9. The composition of claim 1 wherein the ophthalmic drug is selected from the group consisting of anti-glaucoma agents; anti-angiogenesis agents; anti-infective agents; non-steroidal and steroidal anti-inflammatory agents; growth factors; immunosuppressant agents; and anti-allergic agents. 10. The composition of claim 1 wherein the ophthalmic drug is selected from anti-glaucoma agents; anti-angiogenesis agent and anti-allergic agents. 11. An aqueous composition suitable for topical ophthalmic administration comprising: an ophthalmically acceptable drug; a viscosity enhancing amount of a combination of two polymers having a synergistic effect on the composition's viscosity, the combination of two polymers being hydroxypropyl methylcellulose (HPMC) and hydroxyethylcellulose (HEC), wherein the concentration of HPMC is in a range from 0.05 to 0.5% and HEC is in a range from 0.05 to 0.5% wherein the aqueous composition is free of any polymers other than hydroxypropyl methylcellulose and hydroxyethyl cellulose; wherein the aqueous composition has a viscosity that is greater than 150% of a sum of viscosities of two solutions, each of the two solutions respectively including only one of the two polymers. 12. The composition of claim 11 wherein the total concentration of the two polymers ranges from 0.05-3.0% (w/w). 13. The composition of claim 11 wherein the total concentration of the two polymers ranges from 0.2-2.0% (w/w). 14. The composition of claim 13 wherein the concentration of HEC in the composition is in a range from 0.1 to 0.2%. 15. The composition of claim 14 wherein the concentration of HPMC in the composition is in a range from 0.05 to 0.5%. 16. The composition of claim 11 wherein the ophthalmic drug is selected from the group consisting of anti-glaucoma agents; anti-angiogenesis agents; anti-infective agents; non-steroidal and steroidal anti-inflammatory agents; growth factors; immunosuppressant agents; and anti-allergic agents. 17. The composition of claim 11 wherein the concentration of HEC in the composition is in a range from 0.1 to 0.2%. 18. The composition of claim 11 wherein the ophthalmic drug is selected from anti-glaucoma agents; anti-angiogenesis agent and anti-allergic agents.